Standard first-line treatment of ovarian cancer (OC) consists of platinum-taxane combined chemotherapy. However, this regimen only cures about 25% of women with OC. Phase II studies have shown that platinum-gemcitabine doublet and platinum-taxane-gemcitabine triplet regimens are active first-line chemotherapy in advanced OC, with overall response rates (ORR) above 55%. Several phase III studies of gemcitabine-based doublet and triplet chemotherapy in OC are currently underway. Preliminary data show that these regimens are well-tolerated, with manageable haematological toxicity, and the efficacy results are eagerly awaited. Gemcitabine is also active as second-line monotherapy in women with recurrent OC, and studies combining gemcitabine with paclitaxel, docetaxel, liposomal doxorubicin or topotecan resulted in higher ORR than gemcitabine alone. Gemcitabine-cisplatin and gemcitabine-carboplatin are active in women with platinum-resistant recurrent OC suggesting in vivo synergy between these two classes of drug. These studies show that gemcitabine-based chemotherapy may have an important role as second-line treatment in women with platinum-resistant OC. Gemcitabine combinations are also highly recommended as they avoid the problems of neurotoxicity and alopecia seen with other regimens. In order to respect the quality of life of women with recurrent OC, assessment of prognostic factors is recommended so that the most appropriate chemotherapy can be administered.

中文翻译：

---

吉西他滨治疗卵巢癌患者。

卵巢癌（OC）的标准一线治疗包括铂-紫杉烷联合化疗。但是，该方案只能治愈约25％的OC妇女。II期研究表明，铂-吉西他滨双联疗法和铂-紫杉烷-吉西他滨三联疗法是晚期OC中积极的一线化疗方案，总缓解率（ORR）高于55％。目前正在进行数项基于吉西他滨的双联和三联化疗在OC中进行的III期研究。初步数据表明，这些方案耐受性良好，血液毒性可控，亟待疗效。吉西他滨在复发性OC的女性中也作为二线单药治疗，并且吉西他滨与紫杉醇，多西他赛，脂质体阿霉素或托泊替康联合使用的研究产生的ORR高于单独使用吉西他滨。吉西他滨-顺铂和吉西他滨-卡铂在患有铂耐药的复发性OC的女性中活跃，这表明这两类药物在体内具有协同作用。这些研究表明，以吉西他滨为基础的化疗可能对患有铂耐药性OC的女性作为二线治疗起重要作用。还强烈推荐使用吉西他滨组合，因为它们可以避免其他方案出现的神经毒性和脱发问题。为了尊重复发性OC妇女的生活质量，建议评估预后因素，以便可以进行最合适的化疗。这些研究表明，以吉西他滨为基础的化疗可能对患有铂耐药性OC的女性作为二线治疗起重要作用。还强烈推荐使用吉西他滨组合，因为它们避免了其他方案所见的神经毒性和脱发问题。为了尊重复发性OC妇女的生活质量，建议评估预后因素，以便可以进行最合适的化疗。这些研究表明，以吉西他滨为基础的化疗可能对患有铂耐药性OC的女性作为二线治疗起重要作用。还强烈推荐使用吉西他滨组合，因为它们避免了其他方案所见的神经毒性和脱发问题。为了尊重复发性OC妇女的生活质量，建议评估预后因素，以便可以进行最合适的化疗。